MaxCyte宣布裁员34%以削减成本

2025-09-23 04:36

MaxCyte (NASDAQ:MXCT) is implementing a restructuring plan that includes a 34% reduction in its global workforce, including EOR personnel.
The move is aimed at cutting operating expenses, streamlining the organization.
The company expects annualized savings of ~$13.6M from this action.
2025 core revenue is expected to be flat to down ~10% vs. 2024, consistent with prior guidance.
MaxCyte anticipates $5M in SPL program revenue for 2025 and expects to end the year with at least $155M in cash and investments.
MXCT shares down nearly 2% post-market on Monday.
Source: Press release

More on MaxCyte